Altium Capital Management’s Oric Pharmaceuticals ORIC Stock Holding History

Altium Capital Management’s Portfolio ORIC Stock Details ORIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-355,000	Closed	-$2.86M	–	54
2024 Q4	$2.86M	Hold	355,000	–	–	0.81%	37
2024 Q3	$3.64M	Sell	355,000 -50,000	-12%	-$494K	1.07%	35
2024 Q2	$2.86M	Hold	405,000	–	–	1.17%	27
2024 Q1	$5.57M	Sell	405,000 -271,000	-40%	-$3.22M	2.2%	18
2023 Q4	$6.22M	Buy	676,000 +257,294	+61%	+$1.86M	4.22%	9
2023 Q3	$2.53M	Buy	+418,706	New	+$3.43M	1.32%	26

Other funds holding ORIC

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Pfizer New York $239M AUM 232.47% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Altium Capital Management's ORIC Position: Q1 2025 in Review

Altium Capital Management sold out of Oric Pharmaceuticals (ORIC) in Q1 2025, closing a stake of 355,000 shares — an estimated $2.86M sold.

Altium Capital Management first reported a position in ORIC in Q3 2023 and held it in 6 quarters. The position peaked at $6.22M in Q4 2023. 143 funds tracked by Wall St. Rank hold ORIC as of Q1 2025.

Altium Capital Management reported no remaining Oric Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Altium Capital Management sold 355,000 Oric Pharmaceuticals shares in Q1 2025, an estimated $2.86M.
Altium Capital Management first reported a position in Oric Pharmaceuticals in Q3 2023 and held it in 6 quarters.
Altium Capital Management's Oric Pharmaceuticals position peaked at $6.22M in Q4 2023.
143 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q1 2025.

Based on Altium Capital Management's 13F filing for Q1 2025, filed 9 May 2025.